BRKR Bruker Corp
- 76.210
- +2.510+3.41%
Bruker Corp News
Accelerate Diagnostics Inc (AXDX) (Q1 2024) Earnings Call Transcript Highlights: Navigating ...
Commodity trading giant Trafigura Group (Trafigura) announced on May 8 that it has expanded its agreement with Brookfield Asset Management and its listed affiliate Brookfield Business Partners to include Greenergy's Canadian supply business. The exact amo
Commodity trading giant Trafigura Group (Trafigura) announced on May 8 that it has expanded its agreement with Brookfield Asset Management and its listed affiliate Brookfield Business Partners to include Greenergy's Canadian supply business. The exact amount was not disclosed. This is in addition to the proposed acquisition of Greenergy's European business announced by Torque on March 4, 2024. The two acquisitions are also subject to customary closing conditions and regulatory approval.
10x Genomics Stock Slides Amid German Patent Court Ruling
German Federal Patent Court Invalidates European Patent No. 2794928b1 In Germany
German Federal Patent Court Invalidates European Patent No. 2794928b1 In Germany
German Federal Patent Court Invalidates Patent Asserted By 10x Genomics, Delivering Legal Win to NanoString and Bruker
Last Week's Worst-Performing Stocks: Are These 15 Large-Cap Stocks In Your Portfolio? (April 28-May 4, 2024)
These 15 large-cap stocks were the worst performers last week. Are they in your portfolio?CVS Health Corporation (NYSE:CVS) shares tumbled 18.2% after it reported first-quarter sales of $88.4 billion,
Bruker Corporation (NASDAQ:BRKR) Q1 2024 Earnings Call Transcript
Bruker Corp (BRKR) Q1 2024 Earnings Call Transcript Highlights: Navigating Through Acquisitions ...
Earnings Call Summary | Bruker Corp(BRKR.US) Q1 2024 Earnings Conference
The following is a summary of the Bruker Corporation (BRKR) Q1 2024 Earnings Call Transcript:Financial Performance:Bruker reported Q1 2024 revenues of $721.7 million, up 5.3% which was majorly driven
12 Health Care Stocks Moving In Thursday's Intraday Session
GainersEmergent BioSolutions (NYSE:EBS) stock moved upwards by 98.4% to $3.83 during Thursday's regular session. The company's market cap stands at $200.6 million. The company's, Q1 earnings came out
Bruker Shares Fall After Q1 Revenue Misses Consensus Views; Lifts Full-Year Guidance
Bruker (BRKR) shares fell more than 11% in Thursday morning trading after the company reported mixed Q1 results as earnings beat, but revenue fell short of analyst expectations. The company reported Q
Bruker Corp (BRKR) Q1 2024 Earnings: Mixed Results Amidst Strategic Acquisitions
Bruker Shares Are Trading Lower After a Q1 Revenue Miss.
Bruker Shares Are Trading Lower After a Q1 Revenue Miss.
Bruker Updates 2024 Outlook: Now Sees Revenue Of $3.29B-$3.35B (Prior $3.23B-$3.29B) Vs. $3.282B Est.; Sees Adjusted EPS Of $2.79 To $2.84 (Prior $2.71-$2.76) Vs. $2.71 Est.
Fiscal Year 2024 Financial OutlookBruker's FY 2024 updated guidance now includes the expected benefits of the Chemspeed acquisition closed in Q1 2024, and of the ELITech acquisition, which closed on A
Bruker Corp Announces Strategic Acquisition of ELITechGroup
Bruker Sees 2024 Rev $3.29B-$3.35B >BRKR
Bruker Sees 2024 Rev $3.29B-$3.35B >BRKR
Bruker Raises 2024 Revenue Guidance>BRKR
Bruker Raises 2024 Revenue Guidance>BRKR
Earnings Flash (BRKR) BRUKER CORPORATION Posts Q1 Revenue $721.7M, Vs. Street Est of $729M
07:07 AM EDT, 05/02/2024 (MT Newswires) -- Earnings Flash (BRKR) BRUKER CORPORATION Posts Q1 Revenue $721.7M, vs. Street Est of $729M
Bruker Q1 2024 Adj EPS $0.53 Beats $0.46 Estimate, Sales $721.700M Miss $729.879M Estimate
Bruker (NASDAQ:BRKR) reported quarterly earnings of $0.53 per share which beat the analyst consensus estimate of $0.46 by 15.22 percent. This is a 17.19 percent decrease over earnings of $0.64 per sha
Press Release: Bruker Reports First Quarter 2024 Financial Results
Bruker Reports First Quarter 2024 Financial Results -- Q1 2024 revenues of $721.7 million, up 5.3% year-over-year (yoy); organic revenue up 1.6% yoy, and constant-exchange rate (CER) revenu
Analysis
Price Target
No Data
